GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Forward PE Ratio

Artelo Biosciences (Artelo Biosciences) Forward PE Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Forward PE Ratio?

Artelo Biosciences's Forward PE Ratio for today is 0.00.

Artelo Biosciences's PE Ratio without NRI for today is 9999.00.

Artelo Biosciences's PE Ratio for today is 9999.00.


Artelo Biosciences Forward PE Ratio Historical Data

The historical data trend for Artelo Biosciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Forward PE Ratio Chart

Artelo Biosciences Annual Data
Trend
Forward PE Ratio

Artelo Biosciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Artelo Biosciences's Forward PE Ratio

For the Biotechnology subindustry, Artelo Biosciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Forward PE Ratio falls into.



Artelo Biosciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Artelo Biosciences  (NAS:ARTLW) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Artelo Biosciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus

Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd

By Stock market mentor Stock market mentor 01-26-2023